JBM (Healthcare) Limited
JBM (Healthcare) Limited, an investment holding company, develops, manufactures, markets, distributes, and sells healthcare and wellness products in Asia. The company offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter …
Drug Manufacturers - Specialty & Generic
HK, Kwun Tong [HQ]
Ratios
7 Sheets · From 2023 to 2017Configuration
Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | 55.31 | 55.18 | 49.84 | 45.56 | 35.04 | 36.12 | 49.26 | |
| Profit Margin | 16.03 | 17.06 | 10.75 | 5.69 | 6.06 | 10.97 | 20.12 | |
| Operating Margin | 20.26 | 21.63 | 13.59 | 17.85 | 8.95 | 13.02 | 24.35 | |
|
EPS Growth
|
- - | 23.84 | -21.81 | -44.88 | 9.09 | 131.88 | 134.38 | |
| EPS HKD | 4.74 | 5.87 | 4.59 | 2.53 | 2.76 | 6.40 | 15.00 | |
| Return on Assets (ROA) | 3.76 | 4.06 | 3.00 | 1.64 | 1.85 | 4.07 | 9.39 | |
| Return on Equity (ROE) | 43.61 | 35.53 | 6.24 | 2.50 | 2.65 | 5.79 | 13.44 | |
| Return on Invested Capital (ROIC) | 5.90 | 7.11 | 3.79 | 4.56 | 2.51 | 4.87 | 11.99 | |
| Solvency | ||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 59.61 | 49.98 | 34.09 | 17.95 | 14.33 | 11.88 | 9.10 | |
| Debt/Equity | 690.57 | 437.63 | 70.95 | 27.40 | 20.54 | 16.91 | 13.01 | |
| Debt/EBITDA | 737.14 | 574.93 | 432.94 | 151.55 | 170.25 | 24.98 | -3.62 | |
|
Debt/Capitalization
|
87.35 | 81.40 | 41.50 | 21.51 | 17.04 | 14.46 | 11.51 | |
| Long-Term Debt/Capitalization | 10.72 | 5.07 | 40.45 | 16.21 | 11.01 | 6.08 | 4.32 | |
| Interest Debt per Share HKD | 0.75 | 0.72 | 0.52 | 0.29 | 0.22 | 0.20 | 0.15 | |
| Debt Growth | - - | -3.71 | -27.82 | -42.55 | -20.46 | -15.49 | -25.93 | |
| Liquidity | ||||||||
| Current Ratio | 35.21 | 35.20 | 270.50 | 207.31 | 205.84 | 170.08 | 165.88 | |
| Quick Ratio | 31.79 | 32.28 | 206.63 | 172.30 | 168.62 | 142.05 | 124.55 | |
| Cash Ratio | 6.20 | 4.94 | 72.89 | 68.82 | 54.30 | 78.22 | 63.55 | |
| Operating Cash Flow Ratio | - - | - - | - - | - - | - - | - - | - - | |
| Turnover | ||||||||
| Inventory Turnover | 376.74 | 458.73 | 300.05 | 450.30 | 551.11 | 609.21 | 359.23 | |
| Receivables Turnover | 112.70 | 108.99 | 285.69 | 279.85 | 276.25 | 418.75 | 479.76 | |
| Payables Turnover | 1,626.19 | 949.31 | 2,572.78 | 1,661.55 | 1,183.40 | 1,108.45 | 1,483.92 | |
|
Asset Turnover
|
23.48 | 23.79 | 27.89 | 28.75 | 30.48 | 37.08 | 46.69 | |
| Fixed Turnover | 130.18 | 162.46 | 209.76 | 206.20 | 224.25 | 315.05 | 424.08 | |
| Coverage | ||||||||
| Interest Coverage | 3,090.25 | 4,785.61 | 6,135.86 | 957.11 | 567.52 | 825.57 | 1,857.72 | |
| Asset Coverage | - - | - - | 100 | 100 | 200 | 200 | 400 | |
| Cash Flow Coverage (CFGR) | 12.27 | 8.81 | 8.21 | 23.77 | 31.44 | 87.56 | 151.99 | |
| EBITDA Coverage | 4,800 | 7,400 | 10,700 | 1,500 | 1,300 | 1,300 | 2,400 | |
| Dividend Coverage | - - | - - | - - | - - | - - | -1,200 | -200 | |
| Time Interest Earned (TIE) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Market Prospects | ||||||||
| Dividend Yield | - - | - - | - - | - - | - - | 0.46 | 6.63 | |
| Earnings Yield | 2.20 | 2.72 | 2.13 | 1.89 | 3.03 | 5.93 | 16.40 | |
|
Price/Earnings (P/E)
|
4,555.00 | 3,679.75 | 4,705.67 | 5,298.85 | 3,303.23 | 1,686.08 | 609.62 | |
| Price/Earnings Growth (PEG) | - - | 154.35 | -215.80 | -118.07 | 363.35 | 12.78 | 4.54 | |
|
Price/Book (P/B)
|
1,986.60 | 1,307.48 | 293.67 | 132.37 | 87.52 | 97.68 | 81.94 | |
| Price/Tangible Book (P/TB) | 1,986.60 | 1,307.48 | 293.67 | 132.37 | 87.52 | 97.68 | 81.94 | |
| Price/Sales (P/S) | 730.28 | 627.73 | 505.94 | 301.53 | 200.24 | 185.01 | 122.66 | |
|
Price/Cash Flow (P/CF)
|
2,345.40 | 3,391.72 | 5,042.08 | 2,032.10 | 1,355.11 | 659.84 | 414.28 | |
| Price/Free CF (P/FCF) | 2,690.70 | 4,040.19 | 5,717.56 | 3,328.99 | 1,535.72 | 698.80 | 437.56 | |
| Price/Operating CF (P/OCF) | 2,345.40 | 3,391.72 | 5,042.08 | 2,032.10 | 1,355.11 | 659.84 | 414.28 |